Modified vaccinia ankara

EMA approves MVA-BN for mpox and smallpox in adolescents 12-17, second approval for younger population. Clinical study data supported non-inferior immune responses and similar safety profile. Bavarian Nordic plans further trials for younger children.

WHO approved Bavarian Nordic's MVA-BN mpox vaccine for adults, with conditional use for babies, children, teens, and pregnant women in outbreak settings. Critics argue the vaccine's safety and efficacy in pediatric populations are unproven, questioning WHO's approval. The vaccine, sold as Jynneos in the US, is also criticized for diverting resources from broader public health issues in Africa.

WHO prequalifies MVA-BN as first mpox vaccine, aiming to expedite access and control outbreaks. The vaccine, for those over 18, requires two doses four weeks apart and can be stored at 2–8°C for up to eight weeks. This decision aids in fast-tracking approvals and procurement by governments and international agencies.

WHO prequalifies MVA-BN vaccine for mpox, facilitating increased access to combat outbreaks. The vaccine, administered in two doses four weeks apart, has an estimated 82% effectiveness. WHO emphasizes the need for urgent scale-up in procurement and distribution to ensure equitable access, especially in Africa.

WHO approves MVA-BN as first pre-qualified mpox vaccine, with single-dose effectiveness at 76% and two-dose at 82%. WHO chief emphasizes urgent vaccine procurement and roll-out for equitable access.

WHO approves MVA-BN vaccine as first mpox vaccine for prequalification, aiming to facilitate timely access and reduce transmission. The vaccine, administered in 2 doses 4 weeks apart, can be stored at 2–8°C for up to 8 weeks and is recommended for high-risk individuals, including 'off-label' use in children and pregnant women. Single-dose use is advised in supply-constrained situations, with estimated 76% effectiveness pre-exposure and 82% with 2 doses.

Bavarian Nordic’s MVA-BN vaccine is the first mpox vaccine to receive WHO pre-qualification, enabling global use. WHO recommends single doses in supply-constrained situations and 'off label' use for children and immuno-compromised individuals. The vaccine is currently approved for adults, with ongoing studies for younger age groups. Bavarian Nordic aims to produce two million doses by the end of 2024.

WHO approves MVA-BN as the first mpox vaccine on its pre-qualification list, effective at 82% with two doses. The vaccine is recommended for those over 18, with potential off-label use in younger and vulnerable groups. WHO aims to accelerate global access to the vaccine amid ongoing outbreaks.

Bavarian Nordic's IMVANEX® (MVA-BN®) becomes the first mpox vaccine to receive WHO prequalification, facilitating broader access across African countries. The vaccine, indicated for adults, may be used 'off-label' in vulnerable groups during outbreaks. MVA-BN has also received provisional consent from New Zealand and full approval from Mexico.

China's top drug regulator approves Sinopharm's mpox vaccine for clinical trials, potentially marking the country's first experimental dose. The vaccine, developed by the Shanghai Institute of Biological Products, is based on the MVA strain, similar to the Jynneos vaccine approved by the FDA. Currently, no mpox vaccine is approved in China, while globally, a few are approved in the US, Canada, EU, Japan, and Russia. The World Health Organisation declared the mpox outbreak in Africa a public health emergency of international concern.